Ridgefield, CT, United States of America

Ming-Hong Hao

This inventor holds 30 USPTO granted patents and 6 published patent applications, plus 7 CIPO patents and 8 EPO patents, primarily in Cancer Treatment. Top assignees: Boehringer Ingelheim Pharmaceuticals, Inc., Eisai R&d Management Co., Ltd., Boehringer Ingelheim International Gmbh. Active years: 2002-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Ming-Hong Hao. Retrieved from https://idiyas.com/inventor/ming-hong-hao

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 30 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 7 (Patent Applications = 3)

EPO Patents = 8 (Patent Applications = 14)

Average Co-Inventor Count = 6.5

ph-index = 8

Forward Citations = 221(Granted Patents)

Location History:

Ridgefield, CT (US) (2002 - 2015)
Quincy, MA (US) (2016 - 2024)

Company Filing History:

15 out of 278

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

12 out of 530

Eisai R&d Management Co., Ltd.

patents

3 out of 1,562

Boehringer Ingelheim International Gmbh

patents

Years Active: 2002-2025

Loading Chart...

Areas of Expertise:

Bladder Cancer

FGFR4 Inhibitors

Cytokine Inhibitors

Anti-Inflammatory Agents

Pladienolide Compounds

Benzimidazolone Compounds

Tetrasubstituted Alkenes

Thieno-Pyridine Compounds

Benzofuran Compounds

Chymase Inhibitors

Cytokine Mediated Diseases

Heterocyclic Compounds

30 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12251394 - Methods for the treatment of bladder cancer (2025-03-18),

2. 11926619 - Certain pladienolide compounds and methods of use (2024-03-12),

3. 11498916 - Crystalline FGFR4 inhibitor compound and uses thereof (2022-11-15),

4. 11339188 - Compounds for the treatment of cancer (2022-05-24),

5. 10912774 - Pyrimidine FGFR4 inhibitors (2021-02-09),

6. 10851065 - Tetrasubstituted alkene compounds and their use (2020-12-01),

7. 10618930 - Compounds for the treatment of cancer (2020-04-14),

8. 10537571 - Pyrimidine FGFR4 inhibitors (2020-01-21),

9. 10246480 - Compounds for the treatment of cancer (2019-04-02),

10. 9796683 - Tetrasubstituted alkene compounds and their use (2017-10-24),

11. 9730931 - Pyrimidine FGFR4 inhibitors (2017-08-15),

12. 9434697 - Pyrimidine FGFR4 inhibitors (2016-09-06),

13. 9150556 - Benzimidazolone chymase inhibitors (2015-10-06),

14. 8969348 - Chymase inhibitors (2015-03-03),

15. 8420655 - Benzimidazole inhibitors of leukotriene production (2013-04-16),

Title: The Innovative Journey of Ming-Hong Hao

Introduction: Ming-Hong Hao, a talented inventor hailing from Ridgefield, CT (US), has made significant contributions to the world of technology through his groundbreaking innovations.

Latest Patents: Ming-Hong Hao's latest patents focus on advancements in renewable energy technologies, particularly in the field of solar power efficiency and storage solutions.

Career Highlights: With a career spanning over two decades, Ming-Hong Hao has worked for leading tech companies, where he spearheaded research and development projects that have resulted in multiple successful patent applications.

Collaborations: Ming-Hong Hao is known for his collaborative spirit, having worked closely with engineers, scientists, and researchers from various institutions to bring his innovative ideas to life.

Conclusion: Ming-Hong Hao's passion for innovation and his dedication to pushing the boundaries of technology make him a true pioneer in the field of renewable energy and beyond.

Profile summary based on public USPTO records.